Infinity Pharmaceuticals
Khaled Oukasha possesses extensive experience in the pharmaceutical industry, currently serving as Area Manager at Infinity Pharmaceuticals since December 2015. Prior to this role, Khaled held the position of District Manager at Sigma Pharmaceuticals plc - Independent Together from May 2013 to December 2015, and at Delta Pharma from February 2012 to May 2013. Further experience includes a District Manager role at Western Pharmaceutical Industries from October 2010 to February 2012, and a Supervisor position at Pharco Corporation from February 2008 to 2010. Khaled Oukasha holds a Bachelor's degree in Veterinary Medicine from Assiut University, completed in 2004.
This person is not in any offices
Infinity Pharmaceuticals
Infinity Pharmaceuticals, Inc., is a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer in multiple clinical studies.